| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Ioline Henter | Q60962006 |
| Bashkim Kadriu | Q79707210 | ||
| Carlos A Zarate | Q89052847 | ||
| P2093 | author name string | Maurizio Popoli | |
| Laura Musazzi | |||
| Morgan Graves | |||
| P2860 | cites work | Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine | Q38838637 |
| The neurobiology of psychedelic drugs: implications for the treatment of mood disorders | Q22251018 | ||
| The catecholamine hypothesis of affective disorders: a review of supporting evidence | Q22306296 | ||
| A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder | Q24602988 | ||
| Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial | Q24629398 | ||
| A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression | Q24630153 | ||
| Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders | Q24632936 | ||
| Contribution of NMDA receptors to dorsolateral prefrontal cortical networks in primates | Q26820417 | ||
| Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy | Q27024227 | ||
| GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists | Q27025974 | ||
| R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects | Q28266846 | ||
| The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine | Q28276943 | ||
| R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine | Q28303539 | ||
| A Novel Strategy for Continuation ECT in Geriatric Depression: Phase 2 of the PRIDE Study | Q28315355 | ||
| Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice | Q28485938 | ||
| Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice | Q29614979 | ||
| Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report | Q29615999 | ||
| Deep brain stimulation for treatment-resistant depression | Q29616769 | ||
| Antidepressant effects of ketamine in depressed patients | Q29617327 | ||
| A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression | Q29617914 | ||
| mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists | Q29618120 | ||
| NMDAR inhibition-independent antidepressant actions of ketamine metabolites. | Q30370600 | ||
| GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects | Q30440925 | ||
| NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses | Q30471587 | ||
| Synaptic potentiation onto habenula neurons in the learned helplessness model of depression | Q30505460 | ||
| Ketamine-induced brain activation in awake female nonhuman primates: a translational functional imaging model | Q30714646 | ||
| Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis | Q31047296 | ||
| Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants | Q33604879 | ||
| Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks | Q33620630 | ||
| Mechanisms of gamma oscillations | Q33726937 | ||
| BDNF and activity-dependent synaptic modulation | Q33820669 | ||
| A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression | Q34034492 | ||
| Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex | Q34061150 | ||
| Existing and novel biological therapeutics in suicide prevention | Q34085866 | ||
| Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression | Q34112179 | ||
| A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome | Q34166221 | ||
| An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan | Q34259684 | ||
| An open-label trial of riluzole in patients with treatment-resistant major depression | Q34287364 | ||
| A randomized controlled trial of intranasal ketamine in major depressive disorder | Q34288196 | ||
| A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression | Q34315128 | ||
| The definition and meaning of treatment-resistant depression | Q34324114 | ||
| Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression | Q34337526 | ||
| Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder | Q34451408 | ||
| Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity | Q34466181 | ||
| Mortality and suicide risk in treatment-resistant depression: an observational study of the long-term impact of intervention | Q34469254 | ||
| Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review | Q34475595 | ||
| Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study | Q34506620 | ||
| Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression | Q34640885 | ||
| Serial infusions of low-dose ketamine for major depression | Q34648663 | ||
| Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept | Q34653386 | ||
| Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial | Q34655680 | ||
| The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry | Q34660881 | ||
| Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial | Q34661315 | ||
| GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine | Q34729421 | ||
| Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure | Q34744471 | ||
| What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies | Q34879784 | ||
| An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. | Q34881233 | ||
| Ketamine and the next generation of antidepressants with a rapid onset of action | Q34978041 | ||
| Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression | Q35000618 | ||
| Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. | Q35087565 | ||
| Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan | Q35108500 | ||
| Lateral diffusion of Gαs in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains | Q38953906 | ||
| What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. | Q39006234 | ||
| The economic burden of adults with major depressive disorder in the United States (2005 and 2010). | Q39032685 | ||
| Neural Substrates of Depression and Resilience | Q39233337 | ||
| Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression | Q39309191 | ||
| Acute or Chronic? A Stressful Question. | Q39310763 | ||
| Ketamine Treatment and Global Brain Connectivity in Major Depression | Q39413238 | ||
| Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression: Phase 1 of the PRIDE Study. | Q39600223 | ||
| The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits | Q39758341 | ||
| Norepinephrine in depressive reactions. A review | Q40028374 | ||
| Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder | Q40327886 | ||
| Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression | Q40343665 | ||
| The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus | Q40569480 | ||
| Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes | Q40776960 | ||
| The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans | Q41148169 | ||
| Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice | Q41169971 | ||
| The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression | Q41194085 | ||
| Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity | Q41198834 | ||
| Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial | Q41489870 | ||
| Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment | Q41729281 | ||
| Dextromethorphan and quinidine combination in emotional lability associated with depression: a case report. | Q41971188 | ||
| Expression and Dendritic Trafficking of BDNF-6 Splice Variant are Impaired in Knock-In Mice Carrying Human BDNF Val66Met Polymorphism. | Q41999245 | ||
| Physical exercise and antidepressants enhance BDNF targeting in hippocampal CA3 dendrites: further evidence of a spatial code for BDNF splice variants | Q42131316 | ||
| Ketamine's Antidepressant Actions: Potential Mechanisms in the Primate Medial Prefrontal Circuits That Represent Aversive Experience | Q42222900 | ||
| Riluzole enhances glutamate uptake in rat astrocyte cultures | Q42459306 | ||
| A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression | Q42688037 | ||
| Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression | Q43246360 | ||
| Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine | Q43698580 | ||
| Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression | Q44647972 | ||
| mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling | Q45166980 | ||
| Ketamine modulates theta and gamma oscillations. | Q45937104 | ||
| Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). | Q45939966 | ||
| Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers | Q46242157 | ||
| The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. | Q46266275 | ||
| The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders | Q46296210 | ||
| AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist | Q46432100 | ||
| Depression: the best way forward | Q46504314 | ||
| Dopamine System Dysregulation in Major Depressive Disorders. | Q47123548 | ||
| Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. | Q47213622 | ||
| Lateral habenula in the pathophysiology of depression | Q47305152 | ||
| Synaptic Regulation of a Thalamocortical Circuit Controls Depression-Related Behavior. | Q47325157 | ||
| BDNF release and signaling are required for the antidepressant actions of GLYX-13. | Q47331962 | ||
| The PRIDE Study and the Conduct of Electroconvulsive Therapy: Questions Answered and Unanswered | Q47345224 | ||
| Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression | Q47376102 | ||
| The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. | Q47402907 | ||
| Engaging homeostatic plasticity to treat depression | Q47406465 | ||
| Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects. | Q47570724 | ||
| Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial | Q47667772 | ||
| Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression | Q47681695 | ||
| A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder | Q47710967 | ||
| Large-Scale Persistent Network Reconfiguration Induced by Ketamine in Anesthetized Monkeys: Relevance to Mood Disorders | Q47726590 | ||
| BDNF at the synapse: why location matters | Q47762461 | ||
| Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test | Q47964039 | ||
| The role of NMDA receptor and nitric oxide/cyclic guanosine monophosphate pathway in the antidepressant-like effect of dextromethorphan in mice forced swimming test and tail suspension test | Q48023328 | ||
| Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression | Q48065604 | ||
| Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent | Q48094257 | ||
| Blockade of the metabotropic glutamate (mGluR2) modulates arousal through vigilance states transitions: evidence from sleep-wake EEG in rodents | Q48107281 | ||
| Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression | Q48255836 | ||
| Dose- and exposure-response to ketamine in depression | Q48272087 | ||
| Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy | Q48282047 | ||
| Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic | Q48320256 | ||
| Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats | Q48334059 | ||
| The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders | Q48435513 | ||
| GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine. | Q48472517 | ||
| Understanding the burden of depression | Q48634845 | ||
| Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex | Q48728126 | ||
| The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder | Q48733433 | ||
| Dextromethorphan as a potential rapid-acting antidepressant | Q48899797 | ||
| Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. | Q49988922 | ||
| Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. | Q51766804 | ||
| Plasma and platelet excitatory amino acids in psychiatric disorders. | Q52032406 | ||
| Postmortem brain tissue of depressed suicides reveals increased Gs alpha localization in lipid raft domains where it is less likely to activate adenylyl cyclase. | Q52585843 | ||
| Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. | Q52587655 | ||
| Mechanisms of ketamine action as an antidepressant. | Q52658612 | ||
| Convergent Mechanisms Underlying Rapid Antidepressant Action. | Q52667723 | ||
| Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. | Q53076446 | ||
| Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. | Q53819936 | ||
| Effects of a ketamine metabolite on synaptic NMDAR function. | Q55060170 | ||
| Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. | Q55438088 | ||
| NMDAR-independent, cAMP-dependent antidepressant actions of ketamine. | Q55456849 | ||
| The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? | Q56453443 | ||
| Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial | Q57074466 | ||
| Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study | Q57410803 | ||
| Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment | Q58213868 | ||
| Riluzole inhibits the persistent sodium current in mammalian CNS neurons | Q73072440 | ||
| Temporally dissociable effects of ketamine on neuronal discharge and gamma oscillations in rat thalamo-cortical networks | Q88493454 | ||
| Effects of Low Doses of Ketamine on Pyramidal Neurons in Rat Prefrontal Cortex | Q88959699 | ||
| Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression | Q35150163 | ||
| BDNF release is required for the behavioral actions of ketamine | Q35203597 | ||
| Distinct modes of AMPA receptor suppression at developing synapses by GluN2A and GluN2B: single-cell NMDA receptor subunit deletion in vivo. | Q35247785 | ||
| An excitatory synapse hypothesis of depression | Q35563515 | ||
| Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study | Q35892768 | ||
| Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole | Q35944981 | ||
| Spontaneous neurotransmission signals through store-driven Ca(2+) transients to maintain synaptic homeostasis | Q35947971 | ||
| Ketamine for depression: where do we go from here? | Q36223372 | ||
| Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression | Q36233963 | ||
| Novel Glutamatergic Treatments for Severe Mood Disorders | Q36498659 | ||
| An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder | Q36626916 | ||
| Effects of ketamine in treatment-refractory obsessive-compulsive disorder | Q36887096 | ||
| Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial | Q37029155 | ||
| Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders | Q37143117 | ||
| Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories | Q37424333 | ||
| Disrupted habenula function in major depression | Q37617589 | ||
| Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study | Q37644483 | ||
| GABAB receptor coupling to G-proteins and ion channels | Q37775207 | ||
| Synaptic dysfunction in depression: potential therapeutic targets | Q38050123 | ||
| The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. | Q38070233 | ||
| BDNF-induced local protein synthesis and synaptic plasticity | Q38100505 | ||
| Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. | Q38133045 | ||
| Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach | Q38169349 | ||
| A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes | Q38227967 | ||
| The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. | Q38228698 | ||
| Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? | Q38254452 | ||
| A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression | Q38379042 | ||
| Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial. | Q38391263 | ||
| Ketamine safety and tolerability in clinical trials for treatment-resistant depression | Q38422947 | ||
| Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition. | Q38554589 | ||
| Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. | Q38596017 | ||
| Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial | Q38686949 | ||
| Is treatment-resistant depression a useful concept? | Q38696595 | ||
| Targeting glutamate signalling in depression: progress and prospects | Q38743867 | ||
| P433 | issue | 2 | |
| P921 | main subject | treatment-resistant depression | Q7836891 |
| antidepressant | Q76560 | ||
| P304 | page(s) | 119-135 | |
| P577 | publication date | 2019-02-01 | |
| P1433 | published in | The International Journal of Neuropsychopharmacology | Q7742309 |
| P1476 | title | Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments | |
| P478 | volume | 22 |
| Q92878421 | (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism |
| Q92970264 | A Major Role for the Lateral Habenula in Depressive Illness: Physiologic and Molecular Mechanisms |
| Q64285435 | Chronic mild stress induces anhedonic behavior and changes in glutamate release, BDNF trafficking and dendrite morphology only in stress vulnerable rats. The rapid restorative action of ketamine |
| Q61797394 | Editorial for Treatment-Resistant Depression (TRD) |
| Q92571861 | Fast-acting antidepressant-like effects of Reelin evaluated in the repeated-corticosterone chronic stress paradigm |
| Q95323034 | Guanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model |
| Q90069806 | Ketamine Administration Reverses Corticosterone-Induced Alterations in Excitatory and Inhibitory Transmission in the Rat Dorsal Raphe Nucleus |
| Q89964132 | Ketamine Alleviates Postoperative Depression-Like Symptoms in Susceptible Mice: The Role of BDNF-TrkB Signaling |
| Q89548916 | Ketamine: Leading us into the future for development of antidepressants |
| Q91173369 | Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites |
| Q95643364 | Novel Targets for Fast Antidepressant Responses: Possible Role of Endogenous Neuromodulators |
| Q64082982 | Prognosis and improved outcomes in major depression: a review |
| Q90704531 | S-Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain: A Placebo- Controlled Study in Healthy Male Individuals |
| Q100737112 | The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites |
Search more.